Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach

Human T-cell lymphotropic virus type 1 (HTLV-1) is an infectious virus that has been linked to adult T cell leukemia /lymphoma, aggressive CD4-T cell malignancy and many other immune-related medical illnesses. So far, no effective vaccine is known to combat HTLV-1, hence, the current research work w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Muhammad Hamza Tariq, Rashid Bhatti, Nida Fatima Ali, Usman Ali Ashfaq, Farah Shahid, Ahmad Almatroudi, Mohsin Khurshid
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/777da64d4fc845c1b224141ad8ea0d40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:777da64d4fc845c1b224141ad8ea0d40
record_format	dspace
spelling	oai:doaj.org-article:777da64d4fc845c1b224141ad8ea0d402021-11-04T06:49:44ZRational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach1932-6203https://doaj.org/article/777da64d4fc845c1b224141ad8ea0d402021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550388/?tool=EBIhttps://doaj.org/toc/1932-6203Human T-cell lymphotropic virus type 1 (HTLV-1) is an infectious virus that has been linked to adult T cell leukemia /lymphoma, aggressive CD4-T cell malignancy and many other immune-related medical illnesses. So far, no effective vaccine is known to combat HTLV-1, hence, the current research work was performed to design a potential multi-epitope-based subunit vaccine (MEBV) by adopting the latest methodology of reverse vaccinology. Briefly, three highly antigenic proteins (Glycoprotein, Accessory protein, and Tax protein) with no or minimal (<37%) similarity with human proteome were sorted out and potential B- and T-cell epitopes were forecasted from them. Highly antigenic, immunogenic, non-toxic, non-allergenic and overlapping epitopes were short-listed for vaccine development. The chosen T-cell epitopes displayed a strong binding affinity with their corresponding Human Leukocyte Antigen alleles and demonstrated 95.8% coverage of the world’s population. Finally, nine Cytotoxic T Lymphocytes, six Helper T Lymphocytes and five Linear B Lymphocytes epitopes, joint through linkers and adjuvant, were exploited to design the final MEBV construct, comprising of 382 amino acids. The developed MEBV structure showed highly antigenic properties while being non-toxic, soluble, non-allergenic, and stable in nature. Moreover, disulphide engineering further enhanced the stability of the final vaccine protein. Additionally, Molecular docking analysis and Molecular Dynamics (MD) simulations confirmed the strong association between MEBV construct and human pathogenic immune receptor TLR-3. Repeated-exposure simulations and Immune simulations ensured the rapid antigen clearance and higher levels of cell-mediated immunity, respectively. Furthermore, MEBV codon optimization and in-silico cloning was carried out to confirm its augmented expression. Results of our experiments suggested that the proposed MEBV could be a potential immunogenic against HTLV-1; nevertheless, additional wet lab experiments are needed to elucidate our conclusion.Muhammad Hamza TariqRashid BhattiNida Fatima AliUsman Ali AshfaqFarah ShahidAhmad AlmatroudiMohsin KhurshidPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Muhammad Hamza Tariq Rashid Bhatti Nida Fatima Ali Usman Ali Ashfaq Farah Shahid Ahmad Almatroudi Mohsin Khurshid Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
description	Human T-cell lymphotropic virus type 1 (HTLV-1) is an infectious virus that has been linked to adult T cell leukemia /lymphoma, aggressive CD4-T cell malignancy and many other immune-related medical illnesses. So far, no effective vaccine is known to combat HTLV-1, hence, the current research work was performed to design a potential multi-epitope-based subunit vaccine (MEBV) by adopting the latest methodology of reverse vaccinology. Briefly, three highly antigenic proteins (Glycoprotein, Accessory protein, and Tax protein) with no or minimal (<37%) similarity with human proteome were sorted out and potential B- and T-cell epitopes were forecasted from them. Highly antigenic, immunogenic, non-toxic, non-allergenic and overlapping epitopes were short-listed for vaccine development. The chosen T-cell epitopes displayed a strong binding affinity with their corresponding Human Leukocyte Antigen alleles and demonstrated 95.8% coverage of the world’s population. Finally, nine Cytotoxic T Lymphocytes, six Helper T Lymphocytes and five Linear B Lymphocytes epitopes, joint through linkers and adjuvant, were exploited to design the final MEBV construct, comprising of 382 amino acids. The developed MEBV structure showed highly antigenic properties while being non-toxic, soluble, non-allergenic, and stable in nature. Moreover, disulphide engineering further enhanced the stability of the final vaccine protein. Additionally, Molecular docking analysis and Molecular Dynamics (MD) simulations confirmed the strong association between MEBV construct and human pathogenic immune receptor TLR-3. Repeated-exposure simulations and Immune simulations ensured the rapid antigen clearance and higher levels of cell-mediated immunity, respectively. Furthermore, MEBV codon optimization and in-silico cloning was carried out to confirm its augmented expression. Results of our experiments suggested that the proposed MEBV could be a potential immunogenic against HTLV-1; nevertheless, additional wet lab experiments are needed to elucidate our conclusion.
format	article
author	Muhammad Hamza Tariq Rashid Bhatti Nida Fatima Ali Usman Ali Ashfaq Farah Shahid Ahmad Almatroudi Mohsin Khurshid
author_facet	Muhammad Hamza Tariq Rashid Bhatti Nida Fatima Ali Usman Ali Ashfaq Farah Shahid Ahmad Almatroudi Mohsin Khurshid
author_sort	Muhammad Hamza Tariq
title	Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
title_short	Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
title_full	Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
title_fullStr	Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
title_full_unstemmed	Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach
title_sort	rational design of chimeric multiepitope based vaccine (mebv) against human t-cell lymphotropic virus type 1: an integrated vaccine informatics and molecular docking based approach
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/777da64d4fc845c1b224141ad8ea0d40
work_keys_str_mv	AT muhammadhamzatariq rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT rashidbhatti rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT nidafatimaali rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT usmanaliashfaq rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT farahshahid rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT ahmadalmatroudi rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach AT mohsinkhurshid rationaldesignofchimericmultiepitopebasedvaccinemebvagainsthumantcelllymphotropicvirustype1anintegratedvaccineinformaticsandmoleculardockingbasedapproach
_version_	1718445029714821120

Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach

Ejemplares similares